All of Us Research Program
Do you want to change the future of health? The Froedtert & MCW health network is part of the National Institutes of Health All of Us Research Program. It has a simple mission — speed up health research breakthroughs. To do this, All of Us is asking one million people to share their health information. Learn how you can help make a difference by joining the All of Us Research Program.
108 results for "Cancer" and "Gynecologic Cancers"
A Randomized 3-arm Phase II Study Comparing 1) Bendamustine, Rituximab and High Dose Cytarabine (BR/CR), 2) Bendamustine, Rituximab, High Dose Cytarabine and Acalabrutinib (BR/CR-A), and 3) Bendamustine, Rituximab and Acalabrutinib (BR-A) in Patients </= 70 Years Old with Untreated Mantle Cell Lymphoma
Comparison of BR/CR, BR/CR-A, and BR-A in patients under 70 with untreated MCL.
Protocol No
ECOG-EA4181-MCL
Sub Category
Assessment of Carboplatin Clearance Predictors: A PK Study on NCI-Sponsored Clinical Trials or Standard of Care Treatments Using Carboplatin
Understanding how to best calculate the dose of carboplatin given to patients with cancer may help doctors learn how to improve the use of carboplatin in the future.
Protocol No
NRG-GY022
Sub Category
A Multi-Center, Phase II Trial of HLA-Mismatched Unrelated Donor Hematopoietic Cell Transplantation with Post-Transplantation Cyclophosphamide for Patients with Hematologic Malignancies
HLA-Mismatched Unrelated Donor HCT with Post-Transplantation Cyclophosphamide (Access)
Protocol No
NMDP-ACCESS
Sub Category
Phase 1-2, double-Blind, Placebo-controlled, Dose Escalation and Expansion Study of ALVR106 in Addition to standard of Care for the Treatment of High-Risk patients with Respiratory Viral Infections After Hematopoietic Cell Transplant
AlloVir P-106-001 Study in Patients Developing Respiratory Infections Post HSCT
Protocol No
ALLOVIR-P-106-001-RESP
Sub Category
A Phase 1b/2a, Open-label, Dose-escalation Study of the Safety and Efficacy of an Anti-CD38 Antibody Drug Conjugate (STI-6129) in Patients with Relapsed or Refractory Systemic AL Amyloidosis
To assess the safety of STI-6129 in patients with relapse refractory (AL) Amyloidosis. To assess the efficacy of STI-6129 in the treatment of patients with R/R systemic AL Amyloidosis.
Protocol No
SORRENTO-STI-6129-001
GILEAD-GS-US-546-5857-AML: A Phase 3, Randomized, Open-Label Study Evaluating the Safety and Efficacy of Magrolimab in Combination With Azacitidine versus Venetoclax plus Azacitidine in Previously Untreated Patients with TP53 Mutant AML who are Ineligible for Intensive Induction Chemotherapy
Magrolimab plus Azacitidine vs Venetoclax plus Azacitidine in Previously Untreated TP53 Mutant AML
Protocol No
GILEAD-GS-US-546-5857-AML
Sub Category
Phase III Clinical Trial Evaluating De-Escalation of Breast Radiation For Conservative Treatment Of Stage I, Hormone Sensitive, Her2-Negative, Oncotype Recurrence Score Less Than Or Equal To 18 Breast Cancer. DE-escalation of Breast RAdiation (DEBRA)
De-Escalation of Breast Radiation Trial for Hormone Sensitive, HER-2 Negative Breast Cancer with Low Risk of Recurrence
Protocol No
NRG-BR007
Sub Category
A Dose Escalation and Dose Expansion Study of NOX66 Plus Doxorubicin in Anthracycline-naïve, Adult Patients with Soft Tissue Sarcoma - CEP-2
To estimate the maximum tolerated dose (MTD) of NOX66 in combination with doxorubicin. To characterize the safety and tolerability of NOX66 alone and in combination with doxorubicin.
Protocol No
NOXOPHARM-NOX66-004
Sub Category
A Phase 1/2 dose escalation and dose expansion study of BA3011 alone and in combination with Nivolumab in adult and adolescent patients 12 years and older with advanced solid tumors
The purpose of this study is to learn about the safety and effectiveness of an experimental drug called Mecbotamab Vedotin (BA3011) on a variety of cancers that have tested positive for the AXL protein.
Protocol No
BIOATLA-BA3011-001
Sub Category
A Phase 1 Safety and Efficacy Study of ADI-001 Anti-CD20 CAR-engineered Allogeneic Gamma-Delta T Cells in Adults with Refractory B-Cell Malignancies, in Monotherapy and Combination with IL-2.
A Phase 1 Study of ADI-001 in B Cell Malignancies
Protocol No
ADICET-ADI-001-BCELL
Sub Category
IIT-Chhabra-EMBRACE-MM: A Multicenter Phase II Study of Maintenance Belantamab Mafodotin (Blenrep®) after BCMA-Directed Chimeric Antigen Receptor T-Cell Therapy in Patients with Relapsed and/or Refractory Multiple Myeloma (RRMM)
Maintenance post CAR-T for MM
Protocol No
IIT-CHHABRA-EMBRACE-MM
Sub Category
Recognition of Circulating Tumor DNA in Sarcoma
Recognition of Circulating Tumor DNA in Soft Tissue Sarcoma
Protocol No
IIT-BEDI-CTDNA
Sub Category
A Phase II Study of CART-ddBCMA for the Treatment of Patients with Relapsed or Refractory Multiple Myeloma
Phase II Study of CART-ddBCMA for the Treatment of Patients with R/R Multiple Myeloma
Protocol No
ARCELLX-ARC-112A-CART-DDBCMA
Sub Category
A Phase III Randomized Trial of Steroids +Tyrosine Kinase Inhibitor Induction with Chemotherapy or Blinatumomab for Newly Diagnosed BCR-ABL-positive Acute Lymphoblastic Leukemia in Adults
Steroids plus TKI with Blinatumomab or Chemo for Newly Diagnosed BCR-ABL Positive ALL in Adults
Protocol No
ECOG-EA9181-ALL
Sub Category
Phase I Trial of Anti-CD20, Anti-CD19, Anti-CD22 CAR (CAR20.19.22) T-cells for Relapsed, Refractory B-cell Malignancies
Phase I Trial of CAR20.19.22 T-cells in Relapsed, Refractory B-cell Malignancies
Protocol No
IIT-SHAH-TRIPLE-CAR20-19-22
Sub Category
A Phase 1b/2 Dose-Escalation and Cohort-Expansion Study to Determine the Safety and Efficacy of BGB-11417 as Monotherapy, in Combination with Dexamethasone and Carfilzomib/Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma
A Phase 1b/2 Dose-Escalation and Cohort-Expansion Study to
Determine the Safety and Efficacy of BGB-11417 in Combination With Dexamethasone andCarfilzomib/Dexamethasone in Patients With Relapsed/Refractory Multiple Myeloma and t(11;14)
Determine the Safety and Efficacy of BGB-11417 in Combination With Dexamethasone andCarfilzomib/Dexamethasone in Patients With Relapsed/Refractory Multiple Myeloma and t(11;14)
Protocol No
BEIGENE-BGB-11417-105
Phase I, Open Label Study of B-Cell Maturation Antigen (BCMA)-Directed CAR-T Cells in Adult Patients with Relapsed and/or Refractory Multiple Myeloma
BCMA Directed CAR-T Cells in Relapsed And Or Refractory Multiple Myeloma
Protocol No
NOVARTIS-ADPT07A12101BCMA-CART
Sub Category
A Randomized Double-Blind Phase III Study of Ibrutinib During and Following Autologous Stem Cell Transplantation Versus Placebo in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma of the Activated B-Cell Subtype
Ibrutinib Before and After Stem Cell Transplant in Treating Patients With R/R DLBCL
Protocol No
ALLIANCE-A051301-CTN1201
Sub Category
COH-18157-HL: A Phase 2 Front-Line PET/CT-2 Response-Adapted Brentuximab Vedotin and Nivolumab Incorporated and Radiation-Free Management of Early Stage Classical Hodgkin Lymphoma (cHL)
PET CT-2 Response-Adapted Brentuximab Vedotin and Nivolumab and RT Free Management in cHL
Protocol No
COH-18157-HL
Sub Category
A Randomized Phase III Trial of Olanzapine Versus Megestrol Acetate for Cancer-Associated Anorexia
Olanzapine vs Megestrol Acetate for the Treatment of Loss of Appetite Among Advanced Cancer Patients
Protocol No
ALLIANCE-A222004-ANOREXIA
Gilead-GS-US-546-5920: A Phase 2 Multi-Arm Study of Magrolimab Combinations in Patients with Myeloid Malignancies
Magrolimab Combinations in Patients with Myeloid Malignancies
Protocol No
GILEAD-GS-US-546-5920
Sub Category